Loading...
•
Dec 31, 2024
Bicycle Q4 2024 Earnings Report
Bicycle Therapeutics reported financial results for Q4 2024 and provided corporate updates.
Key Takeaways
Bicycle Therapeutics reported promising anti-tumor activity and a differentiated safety profile for zelenectide pevedotin plus pembrolizumab in first-line metastatic urothelial cancer. The company's cash and cash equivalents were $879.5 million as of December 31, 2024, expected to provide financial runway into 2H 2027.
Zelenectide pevedotin plus pembrolizumab show promising anti-tumor activity in first-line metastatic urothelial cancer.
Duravelo-2 dose selection data is expected in 2H 2025.
FDA granted Fast Track designation to zelenectide pevedotin for triple-negative breast cancer and NSCLC.
Cash and cash equivalents of $879.5 million as of December 31, 2024, expected to provide financial runway into 2H 2027.
Forward Guidance
Bicycle Therapeutics is focused on advancing its pipeline and executing its research and development programs.
Positive Outlook
- Continue topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab continue to show promising anti-tumor activity
- Advancing radiopharmaceuticals pipeline, with additional MT1-MMP human imaging data expected in mid-2025
- First EphA2 human imaging data planned for 2H 2025
- Several Phase 1/2 trials expected to start in 2025
- Financial runway into the second half of 2027
Challenges Ahead
- Uncertainties inherent in research and development
- Risk that Bicycle Therapeutics may not realize the intended benefits of its technology, partnerships or NECTIN4 gene-amplification strategy
- Timing of results from clinical trials
- Risk that trials may have unsatisfactory outcomes
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...